Overview of Chronic Pain States {#s1}
===============================

Chronic pain is defined as pain that persists after a normal healing time ([@B67]). Chronic pain can be originated by injury to the somatosensory system (neuropathic pain), degenerative processes, chronic inflammation (e.g., osteoarthritis and rheumatoid arthritis), disease (e.g., cancer pain), or by poorly managed acute pain (e.g., post-surgical and post-traumatic pain). In addition, several genetic conditions (e.g., primary erythromelalgia, paroxysomal extreme pain disorder) may generate persistent chronic pain ([@B27]; [@B11]; [@B62]; [@B72]). Epidemiological studies have shown that chronic pain is a prominent health care issue, affecting around 19% of the adult European population ([@B16]). Furthermore, these studies also have shown that a major part of these patients received inadequate pain management. Chronic pain is characterized by an increased responsiveness to innocuous (allodynia) and to nociceptive stimuli (hyperalgesia), together with episodes of spontaneous pain. Diverse peripheral and central mechanisms contribute to the development and the maintenance of these pain hypersensitivity manifestations \[reviewed in ([@B11]; [@B74]; [@B75]; [@B72])\].

Current Pharmacological Strategies {#s2}
==================================

The current pharmacological therapeutics to manage chronic pain mainly includes non-opioid analgesics and opioids \[reviewed in ([@B68]; [@B38])\]. Weak opioids, such as codeine and tramadol, are used for moderate pain, while severe pain is treated with strong opioids such as morphine and fentanyl ([@B68]; [@B38]). Other groups of commonly used drugs are the anticonvulsants, such as gabapentin and pregabalin ([@B68]). Tricyclic antidepressants and neurotransmitter reuptake inhibitors (e.g., duloxetine and venlafaxine) are also used in neuropathic pain ([@B68]).

A major issue of the long-term use of both non-opioid and opioid analgesics is that pain relief is often achieved at the expense of unwanted adverse events (AEs) ([@B38]). Constipation is the most frequent AE associated with long-term opioid therapy. Other AEs associated with the use of opioids includes effects on the CNS such as delirium, reduced cognition, sedation, respiratory depression, tolerance, addiction, and physical dependence ([@B38]). On the other hand, the prolonged use of tricyclic antidepressants and reuptake inhibitors generates several AEs, such as dry mouth, disturbed vision, constipation, orthostatic hypotension, dizziness, sedation, nausea, and vomiting ([@B68]; [@B38]).

In addition to the AEs described above, the clinical efficacy of the current treatments against chronic pain, particularly those directed to neuropathic pain, is significantly limited ([@B28]). This scenario highlights the imperative need to develop novel effective and safe analgesics. Coincidentally, the expanding knowledge regarding the neurophysiology of the nociceptive pathways in acute and chronic pain conditions have revealed new protein targets to develop such novel analgesics. These targets proteins mainly include G-protein-coupled receptors (GPCRs), enzymes, transporters, and ion channels, including the members of the pentameric ligand-gated ion channels \[reviewed in ([@B72])\].

Pentameric Ligand-Gated Ion Channels {#s3}
====================================

Pentameric ligand-gated ion channels (pLGICs), a family of channels previously known as Cys-loop receptors, are main players of the chemical neurotransmission on the central nervous system ([@B74]; [@B52]; [@B30]). Mammalian pLGICs comprises nicotinic acetylcholine (nAChR), type 3 serotonin (5-HT~3~R), γ-aminobutyric type A (GABA~A~R), and glycine receptors (GlyR) ([@B52]). pLGICs are integral membrane protein complexes composed of five subunits arranged around a central pore. The ion fluxes through pLGICs generate transient changes in the membrane potential, allowing the dynamic control of the neuronal excitability. Recent structural data has revealed a conserved cylinder-shape architecture for all pLGICs, in which five subunits are arranged around a central five-fold axis. Each subunit comprises a large extracellular domain (ECD) which contains the agonist-binding site, four transmembrane domains (TM1--4) which shape the ion pore, a large intracellular domain (ICD) between TM3 and TM4, and a short extracellular C-terminal region ([**Figure 1**](#f1){ref-type="fig"}) ([@B52]; [@B17]; [@B30]). The binding of the agonist to the orthosteric site within the ECD triggers a rapid isomerization (i.e., gating) that results on the transient structural rearrangements of the TM2 and TM3, allowing the passive diffusion of ions through the ion channel pore ([@B4]). The structural transitions involved in the gating process are able to be modified by allosteric modulators, which for example, can reversibly stabilize the open state of the ion channel, potentiating the ionic currents in an agonist-dependent manner ([@B21]).

![Binding sites of analgesic compounds on pLGIC structures. *Top*: The purple structure represent the 5-HT3R (PDB:6HIQ). The black square highlight the tropeine binding site described within the orthosteric site (blue). The green structure represents nAChRs (PDB: 4AQ9). The black squares show two different binding sites for analgesic molecules (ECD and TMD). The binding site within the ECD correspond to the orthosteric binding site. The inset show chemical compounds and toxins-derivate peptides that may interact with residues on the orthosteric site (red). Conversely, the PAM PNU-120596 binds to an intra-subunit cavity in the TMD (yellow). *Bottom*: The cyan structure represents GABA~A~Rs (PDB: 6HUO). The black square shows the binding site of BDZ at the ECD, in the interphase between α and γ subunits. The yellow structure represent GlyRs (PDB: 5TIO). The black squares show three putative binding sites for analgesic compounds. The tricyclic sulfonamides AM-1488 and AM-3607 binds to ECD, in the interphase between two adjacent α subunits. The binding site for DH-CBD has been described within the TMD. The compound 2,6-DTBP has been proposed to interact with α3GlyRs in an ICD a putative binding site.](fphar-11-00167-g001){#f1}

The dysfunction of the neurotransmitter systems associated with the pLGICs has been associated with several CNS disorders, such as schizophrenia, epilepsy, and Alzheimer\'s disease ([@B63]). Additional genetic, electrophysiological, biochemical, and pharmacological studies have linked chronic pain states with the dysfunction of cholinergic, GABAergic, and glycinergic neurotransmission ([@B31]; [@B47]; [@B7]; [@B69]). The prominent role of the pLGICs in chronic pain have been further highlighted by recent evidences showing that several allosteric modulators of nAChRs, GABA~A~Rs, and GlyRs display analgesic effects in behavioral models of chronic pain (summarized in [**Table 1**](#T1){ref-type="table"}). The present work intends to offer a systematic summary of the current state of the pLGIC pharmacology with focus on advances in preclinical chronic pain research.

###### 

Compounds targeting pLGICs with analgesic effects.

  ---------------------------------------------------------------------------------------------------------------------------
  Receptor targeted   Molecule                 Model                            Dose and administration      Reference
  ------------------- ------------------------ -------------------------------- ---------------------------- ----------------
  α7nAChR             PNU-120596               Carrageenan                      0.3--30 mg kg^−1^ (sc)       [@B50]

  CFA                 10--30 mg kg^−1^ (sc)                                                                  

  Comp B              Formalin                 45--60 mg kg^−1^ (sc)            [@B50]                       

  Carrageenan         3--30 mg kg^−1^ (sc)                                                                   

  CFA                 10--30 mg kg^−1^ (sc)                                                                  

  Comp 111            CFA                      10 mg kg^−1^ (iv)                [@B8]                        

  Comp 31             CFA                      10 mg kg^−1^ (iv)                [@B23]                       

  Comp 19\            CFA                      10 mg kg^−1^ (iv)                [@B9]                        
  Comp 21                                                                                                    

  NS6740              CCI                      1--9 mg kg^−1^ (ip)              [@B54]                       

  Formalin            0.1--9 mg kg^−1^ (ip)                                                                  

  Cotx 2.1            PIPN                     1.5 mg kg^−1^ (ip)               [@B42]                       

  Cotx 2.13           PIPN                     2 mg kg^−1^ (ip)                                              

  Cotx 1.1            PIPN                     1 mg kg^−1^ (ip)                                              

  α4β2nAChR           C-9515                   Formalin                         0.003--0.03 mg kg^−1^ (ip)   [@B41]

  CCI                 0.003 mg kg^−1^ (ip)                                                                   

  C163                Formalin                 1--10 mg kg^−1^ (ip)                                          

  Cris-104            STZ-IN                   35 mg kg^−1^ (po)                [@B25]                       

  Formalin            10--100 mg kg^−1^ (po)   [@B65]                                                        

  SNL                 10--100 mg kg^−1^ (po)                                                                 

  α9 α10 nAChR        RgIA4                    Oxaliplatin-induced neuropathy   0.128--80 μg kg^−1^ (sc)     [@B57]

  α2/α3 GABAAR        HZ166                    CCI                              5--480 mg kg^−1^ (ip)        [@B26]

  Zymosan A           16 mg kg^−1^ (ip)                                                                      

  NS11394             Formalin                 0.3--30 mg kg^−1^ (po)           [@B49]; [@B33]               

  SNI                 3--30 mg kg^−1^ (po)                                                                   

  CFA                 1--10 mg kg^−1^ (po)                                                                   

  CCI                 5--30 mg kg^−1^ (po)                                                                   

  L-838417            Formalin                 1--10 mg kg^−1^ (ip)             [@B37]; [@B51]; [@B33]       

  Zymozan             0.1--10 mg kg^−1^ (ip)                                                                 

  CFA                 1--10 mg kg^−1^ (po)                                                                   

  CCI                 10 mg kg^−1^ (po)                                                                      

  SNI                 10 mg kg^−1^ (ip)                                                                      

  SNL                 10 mg kg^−1^ (po)                                                                      

  TPA023              CCI                      1 mg kg^−1^ (po)                 [@B51]                       

  SNL                 10--30 mg kg^−1^ (po)                                                                  

  NDMC                CCI                      3--30 mg kg^−1^ (po)             [@B56]                       

  MP-III-024          Zymozan A                10--32 mg kg^−1^ (ip)            [@B29]                       

  KRM-II-81           Formalin                 30 mg kg^−1^ (ip)                [@B70]                       

  SNL                 50 mg kg^−1^ (ip)                                                                      

  α1/α3GlyR           CBD\                     CFA                              50 mg kg^−1^(ip)\            [@B71]; [@B43]
                      DH-CBD                                                    50 μg (it)                   

  SNL                 100 μg (it)                                                                            

  AM-1488\            SNI                      20 mg kg^−1^ (po)                [@B15]\                      
  AM-3607                                                                       [@B34]                       

  α3 GlyR             2,6-DTBP                 CFA                              90 mg kg^−1^ (it)            [@B2]

  Zymozan A           90 mg kg^−1^ (it)                                                                      

  CCI                 90 mg kg^−1^ (it)                                                                      
  ---------------------------------------------------------------------------------------------------------------------------

nAChR, nicotinic acetylcholine receptor; GABA~A~R, γ-aminobutyric acid type A receptor; GlyR, glycine receptor; NDMC, N-desmethyl clobazam; CBD, cannabidiol; DH-CBD, de-hydroxyl-cannabidiol; 2,6-DTBP, 2,6-di-tert-butylphenol; CFA, Complete Freund\'s Adjuvant; CCI, chronic constriction injury; SNI, spared-nerve injury; SNL, spinal nerve ligation; PIPN, paclitaxel-induced peripheral neuropathy; STZ-IN, streptozotocin-induced neuropathy; po, oral administration; ip, intraperitoneal administration; it, intrathecal administration; sc, subcutaneous administration.

5-HT~3~Rs {#s4}
=========

5-HT~3~Rs are cation-selective pLGICs which mediate neuronal depolarization within the central and peripheral nervous systems ([@B10]; [@B22]). The effects of drugs modulating 5-HT~3~Rs on behavioral assays of chronic pain have not been systemically investigated on preclinical assays in rodent models of chronic pain. However, clinical studies have revealed that the treatment with several 5-HT~3~ antagonists (e.g., alosetron, ondansetron) displayed effective pain management on intestinal bowel syndrome ([@B18]; [@B13]; [@B22]) and fibromyalgia ([@B1]).

nAChRs {#s5}
======

nAChRs are cation-selective ion channels expressed in both peripheral and central nervous system ([@B4]; [@B7]). A total of 17 nAChR subunits (α1--10, β1--4, γ, δ and ϵ) have been identified. The first molecules displaying nAChR-mediated analgesia were nicotine, epibatine, and ABT-594. However, the evaluation of these compounds on clinical trials reported important AEs \[reviewed in ([@B66]; [@B39])\]. Novel compounds targeting three specific subunit combinations of nAChRs (α7,α4β2 and α9α10) have displayed analgesic effects on behavioral chronic pain models with improved AEs profiles in preclinical models. Munro and coworkers showed that the α7-selective agonist (i.e., compound B) and PNU-120596, a selective positive allosteric modulator (PAM) of α7 nAChR, showed analgesic effects in inflammatory pain models ([@B50]). Both compounds dose-dependently reversed the pain hypersensitivity produced by Complete Freund\'s Adjuvant (CFA) injection. The maximal efficacy obtained with both molecules was similar to that produced by diclofenac ([@B50]). Other authors have shown that NS6740, a silent agonist selective for α7nAChR (i.e., a ligand that binds to the orthosteric site but more effectively promotes the conformational changes associated with desensitization than activation), reduced pain hypersensitivity elicited by the paw injection of formalin and by chronic constriction of the sciatic nerve (CCI). Interestingly, these effects were not observed in α7 nAChR knock-out mice and were blocked by the α7nAChR antagonist MLA ([@B54]). A systematic screening of a library of small natural molecules (Greenpharma Natural compound library, Prestwick Chemical, France) combined with structure--activity relationship analysis lead to the discovery of hydroxylated chalcones as new PAMs targeting α7nAChRs ([@B8]; [@B23]; [@B9]). The compound 111 was characterized as a selective α7nAChR PAM (EC~50~ ≈3 μM) by using two-electrode voltage-clamp (TEVC) recordings in *Xenopus* oocytes. Interestingly, compound 111 exerted analgesic activity in CFA-injected rats ([@B8]). Further work studied the compound 31, which displayed an improved potentiation (≈666%, 10 μM of compound) of α7nAChRs-mediated currents ([@B23]). In CFA-injected rats, the compound 31 displayed analgesic effects similar to those obtained with PNU-120596 ([@B23]). However, these chalcone-derivate compounds have low aqueous solubility and short time of action *in vivo* ([@B9]). To solve this issue, Balsera and collaborators reported the characterization of peptide-based carrier prodrugs of these compounds ([@B9]). Despite the electrophysiological evidences showing inhibitory actions on the ACh-evoked currents, two peptide derivatives (i.e., comp19 and comp21) carrying the compound 31 showed a recovery of the mechanical hyperalgesia with a prolonged effect ([@B9]). Conversely, other authors have studied the actions of peptides directly targeting α7nAChRs. For example, cotx2.1, cotx2.13, and coxt1.1 are peptides originated from optimizations of the cone snail toxin BuIA ([@B42]). *In silico* approaches and binding assays have shown that these peptides have a higher affinity for α7nAChRs over other nAChRs conformations. These peptides displayed analgesic effects on models of chemotherapy-induced neuropathy, alleviating the paclitaxel-induced hyperalgesia ([@B42]).

Additional efforts have directed attention to other nAchR subunit combinations. Recently, epibatine analogs with high affinity for α4β2 nAChRs were evaluated in chronic pain models ([@B25]; [@B41]; [@B65]). The analogs C-9515 and C-163 dose-dependently reduced the formalin and the CCI-induced hyperalgesia ([@B41]). Further chemical modifications originated the compound Cris-104, a selective α4β2 ligand with an improved ADME profile ([@B25]). Cris-104 exerted analgesic effects in diverse chronic pain models, such as diabetes-induced neuropathy, spared nerve ligation (SNL), and formalin test ([@B25]; [@B65]). Open field performances showed that the analgesic doses of Cris-104 does not produce significant alterations on the locomotor activity ([@B25]; [@B65]).

On the other hand, nAChRs composed by the subunits α9α10 have shown to be important in the generation of chemotherapy-induced pain. Through the optimization of cone snail venoms toxins, Romero and coworkers generated the peptide RgIA4, which displayed a high potency (IC~50~ ≈ 1 nM) as an antagonist for both human and rodent α9α10nAChRs ([@B57]). RgIA4 has selectivity over other nAChRs conformations, such as α2/3β2/4nAChRs (EC50 \> 10 μM) ([@B57]). Interestingly, repeated subcutaneous injections of RgIA4 prevented the progressive oxaliplatin-induced cold allodynia in rats ([@B57]).

GABA~A~Rs {#s6}
=========

GABA~A~Rs are anion-permeable pLGICs. Activation of GABA~A~Rs hyperpolarizes the membrane potential, contributing to the control of neuronal excitability across the whole CNS ([@B46]). Pentameric GABA~A~Rs are composed by any of 19 different subunits (α1-α6, β1-β3, γ1-3, δ, ϵ, ρ, o). However, a large proportion of GABA~A~Rs are composed by two α-subunits, two β-subunits, and one γ-subunit ([@B46]). GABA~A~R PAMs such as diazepam, a classical benzodiazepine (BDZ), attenuate nociceptive transmission in animal models of chronic pain ([@B35]; [@B36]). However, the use of classical BDZs is hampered by sedation and other side effects occurring mainly as a consequence of the modulation of GABA~A~Rs containing the α1 subunit ([@B58]; [@B45]). Interestingly, an increasing number of reports have shown that a new generation of BDZ-site ligands, with higher selectivity over α2/α3-containing GABA~A~Rs, alleviate inflammatory and neuropathic pain with less adverse effects than classical BDZs ([@B55]; [@B76]). For example, NS11394 is a BDZ-site agonist which have superior efficacy at α3GABA~A~R compared to α1GABA~A~R ([@B48]). NS11394 showed analgesic effects on the formalin test, CFA, and CCI model. However, the administration of the compound also showed a reduction on the locomotor activity and motor performance ([@B49]; [@B33]). Similar studies have shown that non-sedative BDZ-site agonist L-838417 displayed analgesic effects on formalin, Zymozan A, CCI, CFA, and spared nerve injury (SNI) models in rats ([@B37]; [@B51]; [@B33]). Nevertheless, L-838417 possesses low bioavailability and a short half-life in mice ([@B37]; [@B33]). Other studies have characterized additional BDZ-site ligands with improved AE profiles. Studies with TPA023, a BDZ-site agonist which has no α1GABA~A~Rs activity, low levels of α2/3GABA~A~Rs efficacy, and minimal activity at α5GABA~A~Rs significantly increased the paw withdraw threshold in CCI and SNL models of neuropathic pain ([@B51]). Analgesic doses TPA023 did not affect the rotarod performance ([@B6]). HZ166, a BDZ-site ligand with preferentially targeting α2- and α3-GABA~A~R, showed dose-dependent anti-hyperalgesic effects in Zymozan A and CCI models ([@B26]). HZ166 did not generate neither locomotor impairment, sedation, nor tolerance ([@B26]). A newer BDZ-type drug, MP-III-024, is a α2/α3GABA~A~R PAM that displayed analgesic effects in inflamed mice without significant effects on the open field performance ([@B29]). In the same line, KRM-II-81 is another α2/α3-selective GABA~A~R BDZ-site ligand that displayed anti-nociceptive effects in rodents with reduced motor side effects ([@B40]; [@B70]). An intriguing case is N-desmethyl clobazam (NDMC), which was found to be a human metabolite of the clinically used BDZ Clobazam (CBZ). Electrophysiological recordings have shown that NDMC potentiated α2 and α3GABAARs to a considerably higher degree than α1 and α2GABA~A~Rs ([@B56]). Behavioral studies showed that NDMC dose-dependently reduced both thermal and mechanical hyperalgesia in neuropathic animals with no impact on the locomotor activity ([@B56]). Noteworthy, clinical trials performed on chronic lower-back pain patients have shown that CBZ and their metabolites are able to generate analgesia in humans ([@B12]; [@B60]).

GlyRs {#s7}
=====

GlyRs are chloride-permeable ion channels that mediates inhibitory neurotransmission mainly in the spinal cord and brainstem ([@B44]). The human genome encodes four GlyR subunits (α1, α2, α3 and β)([@B44]; [@B77]). Genetic, electrophysiological, and behavioral experiments have shown the presence of dysfunctional α3-containing GlyRs in chronic pain of inflammatory origin ([@B31]). Thus, the selective potentiation of α3GlyR activity through PAMs has emerged as a rational approach to restore glycinergic inhibition ([@B20]; [@B77]). One of the first evidences showing a GlyR-dependent analgesia comes from studies using the synthetic phytocannabinoid derivative de-hydroxyl-cannabidiol (DH-CBD). Systemic application of DH-CBD generated a dose-dependent analgesia on the CFA model in mice ([@B71]). DH-CBD was characterized as a PAM targeting α1/α3GlyRs without psychoactive effects ([@B71]). Interestingly, the analgesic effects of DH-CBD were significantly reduced in α3GlyR knock-out mice ([@B71]). However, Lu and co-workers recently reported that α1GlyR is also involved in the DH-CBD-induced analgesia ([@B43]). These studies characterized a genetically modified mice carrying a mutation in α1GlyR (i.e., S296A), that render the receptor resistant to DH-CBD. Behavioral studies showed that the DH-CBD-induced analgesia in the CFA model was suppressed in the α1S296A GlyR mice ([@B43]).

Other compound targeting GlyRs is 2,6-di-tertbutylphenol (2,6-DTBP), a non-sedative analog of propofol ([@B3]). 2,6-DTBP enhanced the glycine-evoked current of α1/α3GlyRs ([@B2]). In models of inflammatory pain, 2,6-DTBP reduced inflammatory hyperalgesia in an α3GlyR-dependent manner ([@B2]). Interestingly, 2,6-DTBP was able to enlarge the decay time kinetics of glycinergic synaptic currents in dorsal horn neurons from inflamed animals or after the activation of EP2 receptors with PGE2, suggesting the recovery of the spinal glycinergic inhibition as a main mechanism of action ([@B2]). The first glycinergic PAM generated by rational drug design is AM-1488, which is a tricyclic sulfonamide that enhance the GlyR function in recombinant and native systems ([@B15]). The oral administration of AM-1488 reversed the tactile allodynia in SNI model ([@B15]). Noteworthy, these authors achieved the first crystal structure of α3GlyRs bound to a PAM. This seminal study showed the binding of AM-3607, an AM-1488 analog, to the interphase of two α subunits at the ECD ([**Figure 1**](#f1){ref-type="fig"}) ([@B34]).

Conclusions {#s8}
===========

The data summarized here allow us to conclude that the search of novel pLGICs modulators may originate chemical templates for the design and development of clinically relevant analgesics. However, it is important to note that only few studies investigated the molecular sites involved in the allosteric modulation of these new molecules (see [**Figure 1**](#f1){ref-type="fig"}). The combination of functional (e.g., electrophysiology) with structural (e.g., X-ray crystallography or cryo-electron microscopy) studies likely will boost the optimization of these novel compounds, allowing the generation of PAMs with improved potency, efficacy, and subunit-selectivity. Additionally, the generation of translational techniques that ensure a successful transition from *in vitro/in vivo* laboratory experiments to human clinical trials is still a critical issue. The recent development of new stem-cells and gene editing technologies may offer a viable alternative for the study of allosteric modulators using neurons derived from human-induced pluripotent stem cells (hiPSC) of specific patients ([@B14]; [@B53]). Recent evidences have reported that human neurons derived from iPSCs expresses ion channels, including pLGICs. Immunocytochemical and qRT-PCR studies performed on human neurons have shown the expression of genes related with voltage-gated ion channels and some pLGICs, such as GABA~A~Rs and nAChRs. In addition, Ca^2+^ imaging studies and electrophysiological techniques have shown that iPSCs-derived neurons expresses functional pLGICs, providing a suitable platform to study endogenous neuronal ion channels in human neurons for pharmacological studies ([@B32]; [@B24]; [@B64]; [@B19]; [@B73]; [@B5]). Moreover, the development of new gene editing techniques (such as CRISPRs/Cas9) may allow the genetic manipulation of these human-derived neurons, making possible the study of PAMs on mutated pLGICs or to directly examine potential off-targets ([@B59]). However, neurons derived from iPSCs displayed a neonatal expression profile ([@B24]; [@B64]; [@B73]). Thus, future investigations with focus on the generation of iPSCs-neurons of the nociceptive pathway (i.e., sensory neurons, spinal cord neurons) having an adult gene-expression profile may provide an excellent platform to further explore the pharmacological modulation of pLGICs and other ion channels by novel allosteric modulators.
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